Anika Therapeutics, Inc. provided revenue guidance for the fiscal year 2022. For the year, the company expects overall revenue to be toward the upper end of its guidance range of low to mid-single digit percent growth compared with 2021.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
24.57 USD | -0.49% | -3.27% | +8.43% |
05-08 | Transcript : Anika Therapeutics, Inc., Q1 2024 Earnings Call, May 08, 2024 | |
05-08 | Earnings Flash (ANIK) ANIKA THERAPEUTICS Reports Q1 EPS $0.09 | MT |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+8.43% | 364M | |
-2.00% | 90.02B | |
-1.18% | 39.15B | |
-15.83% | 31.71B | |
+62.86% | 26.47B | |
-21.68% | 14.34B | |
-8.73% | 12.89B | |
-15.05% | 11.18B | |
-45.69% | 10.97B | |
+4.94% | 8.94B |
- Stock Market
- Equities
- ANIK Stock
- News Anika Therapeutics, Inc.
- Anika Therapeutics, Inc. Provides Revenue Guidance for the Fiscal Year 2022